Novartis AG (NVS) To Present New Data on Kesimpta at ECTRIMS 2025 in Barcelona

​Novartis AG (NYSE: NVS) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 24, ...
Novartis

Bringing breakthroughs to more patients

At Novartis, we don’t just discover life-changing medicines, we're part of a broader effort to help ensure medicines reach the people who need them most, wherever they live, because the true value of ...

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to ...
TipRanks on MSN

Novartis to launch direct-to-patient platform for Cosentyx in U.S.

Novartis (NVS) announced plans to launch a direct-to-patient platform in the U.S. which will come into effect on November 1, offering cash-paying ...
AGDAILY

EPA registers new tool against growing varroa mite threat

The U.S. Environmental Protection Agency has approved the registration of Norroa, the first-ever RNA-based treatment for ...